中重度甲状腺眼病健康状态的效用评估
该定性研究于2020年4月20日至2021年4月29日开展,基于2项安慰剂对照临床试验(171例甲状腺眼病患者,临床活动度评分≥4,伴或不伴复视/突眼)确定6种不同严重程度的健康状态,经美国甲状腺眼病患者(n=6)、患者倡导者(n=3)和医师专家(n=3)访谈验证,对一般人群进行时间权衡法访谈以获取效用值。共111名参与者完成时间权衡访谈,平均(SD)效用值为0.44(0.34),最严重状态(持续性复视/大突眼)效用值最低为0.30(95%CI 0.24-0.36),最轻状态(无复视/小突眼)最高为0.60(95%CI 0.54-0.67)。作者认为活动性中重度甲状腺眼病患者可能存在显著效用损失,突眼/复视严重程度增加更可能与生活质量负相关。
要点
- 研究采用时间权衡法评估6种甲状腺眼病健康状态的效用值,共111名一般人群参与者完成访谈。
- 最严重状态(持续性复视/大突眼)效用值0.30(95%CI 0.24-0.36),最轻状态(无复视/小突眼)0.60(95%CI 0.54-0.67)。
- 作者认为这些健康状态评分可为评估新疗法对甲状腺眼病患者生活质量改善(效用增益)提供基线。
核心结论
- 作者认为活动性中重度甲状腺眼病患者可能存在显著效用损失,突眼/复视严重程度增加更可能与生活质量负相关。
- 作者认为这些健康状态评分可为确定这些甲状腺眼病健康状态经新疗法治疗后的生活质量改善(效用增益)提供基线。
研究设计与样本
- 该定性研究于2020年4月20日至2021年4月29日开展,采用时间权衡法评估健康状态效用值。
- 从2项安慰剂对照临床试验(171例甲状腺眼病患者,临床活动度评分≥4,伴或不伴复视/突眼)确定6种不同严重程度的健康状态,并经美国甲状腺眼病患者(n=6)访谈进行细化。
- 每种健康状态描述经额外的甲状腺眼病患者倡导者(n=3)和医师专家(n=3)访谈验证。
- 健康状态描述和生活质量问卷在一般人群中进行预试验并施测,同时施测视觉模拟量表(VAS)以检测结果的一致性。
主要发现
- 共111名参与者完成时间权衡访谈,平均(SD)效用值为0.44(0.34)。
- 最严重疾病状态(持续性复视/大突眼)平均效用值最低,为0.30(95%CI 0.24-0.36)。
- 持续性复视/小突眼效用值为0.34(95%CI 0.29-0.40),间歇性或非持续性复视/大突眼为0.43(95%CI 0.36-0.49)。
- 无复视/大突眼效用值为0.46(95%CI 0.40-0.52),间歇性或非持续性复视/小突眼为0.52(95%CI 0.45-0.58)。
- 最轻疾病状态(无复视/小突眼)平均效用值最高,为0.60(95%CI 0.54-0.67)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings. MAIN OUTCOMES AND MEASURES: TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests. RESULTS: A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies.
引用
- Smith TJ, Cockerham K, Lelli G, et al. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States. JAMA Ophthalmol. 2023. PMID: 36580313. doi:10.1001/jamaophthalmol.2022.3225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。